Although gastric cancer is one of the most common malignancies worldwide, little is known on the molecular process of its development and progression. This study investigates the involvement of guanine nucleotide exchange factor Vav3 in tumor progression and in the prognosis of human gastric cancer. The two patient cohorts in this study consisted of 167 gastric cancer cases from 1997 through 2001, documenting pathologic and clinical factors, as well as the clinical outcomes. Immunohistochemistry, reverse transcription PCR, immunoblotting, and immunofluorescence were used to examine Vav3 expression in tumor and nontumor pairs of gastric tissues and gastric cell lines. Small hairpin RNA (shRNA) technology was used to study the effects of Vav3 knockdown on the growth and spread of gastric cancer cells. Finally, xenograph proliferation was used to study the tumor growth. Overexpression of Vav3 was associated with the depth of invasion (P ¼ 0.0004), nodal status (P ¼ 0.0260), distant metastasis (P ¼ 0.0003), stage (P ¼ 0.0002), and vascular invasion (P ¼ 0.0286); and correlated with poor disease-free survival (P < 0
Introduction
Gastric cancer is a very common disease worldwide and the second most frequent cause of cancer death, affecting about one million people per year. However, different continents exhibit large differences in incidence (1) . In Asia and parts of South America, in particular, gastric cancer is the most common epithelial malignancy and a leading cause of cancer-related deaths. In Taiwan, gastric cancer ranks as the sixth most frequently diagnosed malignancy and causes more than 2,000 deaths annually (2010 Statistics of causes of death, Department of Health, Taiwan. http://www.doh. gov.tw/statistic/index.htm; accessed in September 2011). Despite current surgical techniques and chemotherapy, which have made significant improvements in gastric cancer treatment, the cure rate for advanced gastric cancer remains low, and the morbidity remains high (2, 3) . Thus, advances in the treatment of this disease are likely to come from a fuller understanding of its pathogenesis and biologic features.
The most important prognostic marker of gastric cancer currently available is the American Joint Committee on Cancer (AJCC) stage determined by the depth of invasion, the involvement of the lymph nodes, and distant metastasis. However, prognosis varies among patients of the same stage. This had led researchers to search for specific biologic markers to identify subgroups of patients with a more aggressive course of disease (4) . Many studies over the last few decades suggest that genetic alterations may play a role in the development and progression of gastric cancer (5) . Thus, molecular pathology may be helpful to understand the disease pathogenesis and provide useful prognostic molecular markers. Potential biologic prognostic markers include overexpression of 14-3-3o, VEGF, mesothelin, EGF receptor, and elevated plasma level of osteopontin (6) (7) (8) (9) (10) .
Vav3 oncogene, a guanine nucleotide exchange factor (GEF) for Rho family GTPases, belongs to Vav family proteins (11) . The 3 mammalian Vav proteins (Vav1, Vav2, and Vav3) differ in their tissue distribution. Vav1 is primarily expressed in hematopoietic cells, whereas Vav2 and Vav3 are more ubiquitously expressed (12) (13) (14) . Vav proteins contain multiple function motifs and are involved in various cellular signaling processes, including cytoskeleton organization, cell transformation, and oncogenesis (15, 16) . Research related to the prognostic value of Vav proteins is limited. Overexpressed Vav1 is an independent prognostic marker for pancreatic cancer (17) . Although the gene amplification and protein overexpression of Vav3 appear in several human cancers, including breast cancer, glioblastoma, and prostate cancer, the clinicopathologic correlation and prognostic significance of Vav3 in human cancers remain unclear (18) (19) (20) . In the present study, to clarify the clinical significance of Vav3 in gastric cancer, we carried out the immunohistochemical analysis of its expression in 167 primary gastric cancer specimens and analyzed its possible association with the clinicopathologic parameters of the tumors as well as with patients' survival. We found that Vav3 overexpression directly correlated with several clinicopathologic parameters and decreased survival. We also found that knockdown of Vav3 expression suppressed the growth, spread, and xenograph proliferation. Our clinical and mechanistic data indicates that Vav3 is a significant prognostic marker, and targeting of Vav3 constituted a potential treatment modality for human gastric cancer.
Patients and Methods

Study subjects
Paraffin-embedded specimens of gastric cancer tissue from 103 consecutive patients who underwent surgical resection of gastric cancer at Taipei Medical University Hospital (Taipei, Taiwan) between 1997 and 2001 were studied retrospectively. Among 103 patients with gastric cancer, follow-up information was available for 59 patients (data set one). The expression of Vav3 was validated using an independent cohort of 235 consecutive patients who underwent surgical resection of gastric cancer at Chi Mei Medical Center (Tainan, Taiwan) from 1997 through 2001. Among 235 patients with gastric cancer, follow-up information was available for 118 patients (data set two). None of these patients had received preoperative chemotherapy and/or radiotherapy. The clinicopathologic parameters of gastric cancer were determined on the basis of AJCC classification. Clinical outcome end points included overall survival and disease-free survival. The follow-up duration for overall survival was defined as the period between the operation date and day of the last visit, according to the patient's chart. For disease-free survival, the follow-up duration was defined as the period between the operation date and date of relapse. The final date of follow-up was 18 August 2010 for the cases. In data set one, a retrospective power analysis was carried out to determine the association of Vav3 expression and overall survival and showed that the study had approximately 98% power to detect a significant difference (effect size ¼ 0.53) given the observed data, assuming a significance level of a ¼ 5%. Table 1 summarizes the clinical features of these 2 cohorts of patients. This study was approved by the Institutional Review Boards of both hospitals, with written ethical consent from all patients. Tumor and nontumor pairs of gastric tissues were analyzed for Vav3 expression.
Immunohistochemical analysis
Paraffin-embedded sections were stained with a primary antibody, polyclonal anti-Vav3 (Millipore), at 4 C overnight at a dilution of 1:500 (18) . A standard peroxidaseconjugated streptavidin-biotin method was used to detect the immunoreactivity (Dako REAL EnVision Detection System; Dako). Colon cancer was used as a positive control for Vav3. The negative control consisted of the omission of the primary antibody and incubation with 1Â PBS. After incubation with 3,3 0 -diaminobenzidine, the sections were counterstained and mounted for microscopic interpretation. Following the method in a previous study, immunoreactivity was scored as follows: 0, no staining; 1, weak and focal staining in less than 25% of tissue; 2, moderate staining in 25% to 50% of tissue; 3, strong staining in more than 50% of tissue (18) . Sections with a score of 0 or 1 had a low expression of Vav3, and those with a score of 2 or 3 were defined as high expression or overexpression of Vav3. Clinical data collection and immunohistochemical analysis were conducted independently in an investigator-blinded study.
Cell culture and small hairpin RNA treatment
Human normal (Hs738.St/Int) and gastric cancer cell lines (AGS and NCI-N87) were obtained from the American Type Culture Collection (ATCC). Cell lines were authenticated by the ATCC cell biology program and were not passaged for longer than 6 months before bringing new cells out of freeze or purchasing a new cell aliquot from the ATCC. Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Hs738.St/Int), F-12K (AGS), or RPMI-1640 (NCI-N87) media supplemented with 10% FBS, 100 units/mL penicillin G, 100 mg/mL streptomycin sulfate, and 250 ng/mL amphotericin B. For small hairpin RNA (shRNA) treatment, AGS cells were infected with lentiviral vectors (3 Vav3-shRNA construct, clone ID: TRCN0000047698, TRCN0000047700, TRCN0000047701; one scrambled control, clone ID: pLKO_TRC025; purchased from the National RNAi Core Facility) and stable clones resistant to puromycin (Santa Cruz; 4 mg/mL) were selected. Total RNA and total cell lyates were extracted, and reverse transcription (RT)-PCR and immunoblotting were then carried out to evaluate the effects of shRNA treatment.
Immunoblotting
Total cell lysates were extracted with RIPA buffer (Pierce). Denatured protein samples were subjected to 10% SDS-PAGE and transferred to nitrocellulose membranes. Blocked blots were incubated at 4 C overnight with anti-Vav3 polyclonal antibody (1:500 dilution). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Millipore; 1:20,000 dilution) was used as an internal control for equal protein loading. After incubation with secondary antibodies conjugated with peroxidase (Sigma), enhanced chemiluminescence reagents (Pierce) were used to visualize the targeted proteins. All experiments were conducted 3 times independently.
RNA extraction and RT-PCR analysis
Total RNA from Vav3 knockdown and scrambled control AGS cells was extracted with TRIzol reagent according to the manufacturer's protocol (Sigma). After chloroform separation, the aqueous phase was collected and RNA was precipitated by adding ice-cold isopropanol. After washing once with 75% ethanol, the pellets were air dried to determine RNA concentrations. cDNA was synthesized from total RNA using a QuantiTect Reverse Transcription Kit (Qiagen), following the instructions of the manufacturer. Total RNA was mixed with genomic DNA Wipeout Buffer and incubated at 42 C for 2 minutes. Quantiscript RT Buffer, RT Primer Mix, and Quantiscript Reverse Transcriptase were added and incubated at 42 C for additional 30 minutes. Synthesized cDNA and the following primers were used to detect Vav3 expression: forward primer: 5 0 -CGA ACA CCT ATA GCA GCC GC-3 0 and reverse primer: 5 0 -GGT GGA GAA GTC TAT GAG GAC-3 0 . The annealing temperature for Vav3 was 54. 4 C. The RT-PCR products were separated by 0.5Â Tris-borate EDTA (TBE) agarose gel electrophoresis and visualized by staining with 0.5 mg/mL ethidium bromide. All experiments were carried out in triplicate.
Immunofluorescence
Vav3 knockdown and scrambled control AGS cells were grown in chamber slides (Millipore). Fix cells with acetone at 17 (29) 21 (44) (Continued on the following page) 
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C for 5 minutes. After blocking, fixed cells were incubated at 4 C overnight with anti-Vav3 polyclonal antibody (1:50 dilution). Goat anti-rabbit IgG conjugated to fluorescein isothiocyanate (FITC; Life Technologies) at a concentration of 0.25 mg/mL was used as secondary antibody. After counterstained with 4 0 ,6-diamidino-2-phenylindole, the slides were mounted and photographed (Â200 magnification).
Cell proliferation assay
Vav3 knockdown and scrambled control AGS cells were seeded into 6-well plates and cultured for 12 days. Individual colonies (>50 cells per colony) were fixed, stained with a solution of 1% crystal violet in methanol, and counted. The assay was conducted 3 times and presented as mean AE SD.
Wound-healing assay
For the wound-healing assay, Vav3 knockdown and scrambled control AGS cells were seeded into a 12-well culture dish and grown to a nearly confluent cell monolayer. The monolayers were carefully scratched with a 200 mL pipette tip. Cellular debris was removed by washing with 1Â PBS, and the cells were then incubated for 18 hours. The cultures were photographed (Â100 magnification) at 0 and 18 hours to monitor the migration of cells to the wounded area, and the number of migrated cells was quantified with ImageJ software. All experiments were carried out in triplicate and presented as mean AE SD.
In vitro invasion assay
The invasion capabilities of AGS cells were examined by a Cell Invasion Assay Kit (Millipore), following the instructions of the manufacturer. Complete media were first added to 24-well plates. Vav3 knockdown and scrambled control AGS cells in serum-free media were added to ECMatrix-layered cell culture inserts (containing 8-mm pore size polycarbonate membranes) and cultured for 24 hours. Inserts were then dipped in the staining solution to stain invaded cells on the lower surface of the membranes. The cultures were photographed (Â100 magnification), and the number of invaded cells was counted. The assay was conducted 3 times independently and presented as mean AE SD.
Gelatin zymography assay
The activities of matrix metalloproteinase (MMP)-2 and MMP-9 in the medium were measured by gelatin zymography protease assays, as previously detailed (21) . Briefly, Vav3 knockdown and scrambled control AGS cells (3 Â 10 5 cells) were seeded into 12-well plates and grown in F-12K containing 10% FBS to a nearly confluent cell monolayer. Collected media of an appropriate volume (adjusted by vital cell number) were prepared with SDS sample buffer without boiling or reduction, and 1 mg/mL gelatin was added and subjected to 8% SDS-PAGE. After electrophoresis, gels were washed with 2.5% Triton X-100 and then incubated in the developing buffer (50 mmol/L Tris-base, 200 m mmol/L NaCl, 5 m mmol/L CaCl 2 , and 0.02% Brij 35) at 37 C for 24 hours. Then, the gels were stained with Coomassie brilliant blue R-250.
Animals
Six 5-week-old male athymic nude mice (BALB/c nu/nu) were purchased from National Laboratory Animal Center, Taiwan. The animals were kept caged in a specifically designed pathogen-free isolation facility with a 12/12-hour light-dark cycle and provided with rodent chow and water ad libitum. All experiments were conducted in accordance with the guidelines of the China Medical University Animal Ethics Research Board.
Tumor cell inoculation
Animals were divided into 2 groups (3 mice per group) for tumor cell inoculation. Vav3 knockdown and scrambled control AGS cells (5 Â 10 6 ) were mixed in a 200 mL matrix gel and injected subcutaneously on the right hind flank. The mice were photographed and sacrificed 9 weeks after inoculation. The tumors were then removed and weighed.
Statistical analysis
The difference in Vav3 expression between tumor and nontumor tissues in the same patient was analyzed using a paired t test. The differences in the growth, migration, and invasion between Vav3 knockdown and scrambled control cells were also analyzed using a paired t test. This study examines some clinicopathologic parameters, including age, gender, depth of invasion, nodal status, distant metastasis, stage, degree of differentiation, and vascular invasion. The correlation between Vav3 expression and clinicopathologic parameters was examined with the c 2 test. Survival analysis was first conducted using the Kaplan-Meier method and the significance was then determined by log-rank test (22) . The Cox proportional hazards model was used for uni-and multivariate analysis to determine the relative prognostic effect of Vav3 and other potential prognostic markers (23) . The assumption of proportionality of hazards functions was assessed with graphical methods as suggested (24) . All the data were analyzed with SPSS version 12.0 (SPSS, Inc.). All statistic tests were 2-sided, and a P value of less than 0.05 was considered significant.
Results
Vav3 expression was upregulated and associated with several clinicopathologic parameters in gastric cancer
This study investigates the expression of Vav3 immunohistochemically in 2 cohorts of patients. Vav3 expression was higher in tumor tissues than in nontumor tissues in both data sets (P < 0.001). Data set two revealed a high expression or overexpression of Vav3 in 45% of tumors (20% with a score of 2 and 25% with a score 3). Twenty-seven percent of the tumors were totally negative (score 0), and the remaining 28% were weak and focal staining in less than 25% of tissues (score 1; Fig. 1A-C) . Three gastric cells were used to confirm the results obtained by immunohistochemistry. Immunoblotting revealed that the expression of Vav3 was higher in (Fig. 1D) . Table 1 summarizes the clinical features of these 2 cohorts of patients. In data set one, the overexpression of Vav3 had a statistically significant correlation with depth of invasion (P ¼ 0.0151), nodal status (P ¼ 0.0089), distant metastasis (P ¼ 0.0087), stage (P ¼ 0.0018), and vascular invasion (P ¼ 0.0066). In data set two, the overexpression of Vav3 had a statistically significant correlation with depth of invasion (P ¼ 0.0004), nodal status (P ¼ 0.0260), distant metastasis (P ¼ 0.0003), stage (P ¼ 0.0002), and vascular invasion (P ¼ 0.0286). There was no significant association between overexpression of Vav3 and age, gender, and degree of differentiation.
Vav3 overexpression and patient survival in data set one Figure 2 shows the correlations of clinical outcomes with Vav3 expression. In data set one, inferior overall survival was significantly associated with overexpression of Vav3 (P ¼ 0.0068; Fig. 2A) . At 3 years, 16 Vav3-low patients were at risk, and the overall survival was 0.7306 [95% confidence interval (CI), 0.5587-0.9025]; 5 Vav3-high patients were at risk, and the overall survival was 0.3356 (95% CI, 0.1184-0.5528). At 5 years, 13 Vav3-low patients were at risk, and the overall survival was 0.6784 (95% CI, 0.4908-0.8660); 3 Vav3-high patients were at risk, and the overall survival was 0.3356 (95% CI, 0.1184-0.5528). Table 2 summarizes the univariate analysis of prognostic markers and patient survival in data set one. Depth of invasion (P < 0.001), nodal status (P ¼ 0.005), distant metastasis (P < 0.001), stage (P < 0.001), vascular invasion (P ¼ 0.004), and overexpression of Vav3 (P ¼ 0.010) were correlated significantly with overall survival.
Validation of Vav3 overexpression for survival prediction by data set two
In data set two, inferior overall and disease-free survival were significantly associated with overexpression of Vav3 (P ¼ 0.0006 and <0.0001, respectively; survival, at 3 years, 22 Vav3-low patients were at risk, and the overall survival was 0.7818 (95% CI, 0.6571-0.9065); 6 Vav3-high patients were at risk, and the overall survival was 0.4962 (95% CI, 0.3318-0.6606). At 5 years, 8 Vav3-low patients were at risk, and the overall survival was 0.6450 (95% CI, 0.4439-0.8461); 3 Vav3-high patients were at risk, and the overall survival was 0.4962 (95% CI, 0.3318-0.6606). For disease-free survival, at 3 years, 22 Vav3-low patients were at risk, and the disease-free survival was 0.6458 (95% CI, 0.5159-0.7757); 6 Vav3-high patients were at risk, and the disease-free survival was 0.3063 (95% CI, 0.1497-0.4629). At 5 years, 8 Vav3-low patients were at risk, and the disease-free survival was 0.6458 (95% CI, 0.5159-0.7757); 3 Vav3-high patients were at risk, and the disease-free survival was 0.2552 (95% CI, 0.0959-0.4145). Table 3 summarizes the univariate analysis of prognostic markers and patient survival in data set two. Depth of invasion (P < 0.001), nodal status (P < 0.001), distant metastasis (P < 0.001), stage (P < 0.001), vascular invasion (P < 0.001), and overexpression of Vav3 (P < 0.001) were correlated significantly with disease-free survival.
The association between overexpression of Vav3 and disease-free survival remained significant even after controlling for other well-known prognostic markers in multivariate analysis (Table 3) . In multivariate analysis, overexpression of Vav3 was prognostically independent (HR, 2.051; 95% CI, 1.060-3.970; P ¼ 0.033), along with depth of invasion (HR, 3.284; 95% CI, 1.465-7.359; P ¼ 0.004), nodal status (HR, 3.307; 95% CI, 1.168-9.358; P ¼ 0.024), and distant metastasis (HR, 8.047; 95% CI, 2.974-21.777; P < 0.001).
Effect of Vav3 overexpression on the prognosis in highstage gastric cancer
Tumor stage is the most important prognostic marker of gastric cancer. To find out the effect of Vav3 overexpression on the prognosis in high-stage gastric cancer (stage III and IV), we used the combined samples of data set one and two for this analysis. We found that high-stage gastric cancer concomitant with Vav3 overexpression had a significantly lower 5-year overall survival rate than high-stage gastric cancer without Vav3 overexpression (Fig. 3A , P ¼ 0.0083), whereas low-stage gastric cancer (stage I and II) had a better 5-year overall survival rate, regardless of the expression status of Vav3 (Fig. 3B, P ¼ 0.1002) .
Effects of knockdown of Vav3 on gastric cancer cell growth, spread, and xenograph proliferation
This study also investigates the involvement of Vav3 in the growth and spread of AGS gastric cancer cells, and in vivo tumor growth in nude mice, using shRNA technology to specifically knockdown Vav3 (Fig. 4A-C) . Because the efficiency of Vav3 knockdown was similarly high (>95%) in 3 clones, one clone (clone ID: TRCN000047698) was (Fig. 5A, P < 0.0001) . The profile of the DNA content of the Vav3 knockdown AGS cells, obtained using flow cytometric analysis, also indicated that the cell cycle was arrested in the G 2 -M phase (data not shown). The wound-healing assay revealed a significant delay in wound closure after Vav3 knockdown compared with scrambled control (Fig. 5B, P ¼ 0.0058 ). In the cell invasion assay, Vav3 knockdown significantly suppressed cell invasion compared with scrambled control (Fig. 5C, P ¼ 0.0372) . In addition, gelatin zymography assay shows that Vav3 knockdown significantly inhibited the activities of MMP-2 and MMP-9 (2 metalloproteinases involved in the degradation of the basement membrane and are essential to the invasion process) compared with scrambled control (Fig. 5D) . Finally, the growth of AGS xenograph was significantly inhibited after Vav3 knockdown compared with scrambled control (Fig. 5E , P ¼ 0.0433).
Discussion
Gastric cancer still remains a major public health problem throughout the world (1). Current treatment protocols have little efficacy on advanced disease where the 5-year survival rate is less than 30% (25, 26) . A better knowledge of the molecular mechanisms underlying the development of this deadly neoplasm is therefore needed to devise novel prevention and intervention strategies. In particular, identification of the molecules that are altered during cancer initiation and progression can provide valuable tools as prognostic markers or therapeutic targets.
Vav proteins regulate many cellular events, including actin remodeling, cell transformation, and oncogenesis (15, 16, 27) . This study investigates the expression levels of Vav3 in gastric tissues from patients with gastric cancer. As in previous studies on other types of cancer, the results of this study show that Vav3 expression was higher in tumor gastric tissues than in nontumor gastric tissues (18) (19) (20) . In addition, immunoblotting results confirm that the Vav3 expression in gastric cancer cells was higher than that in normal gastric cells. The current study shows that overexpression of Vav3 in gastric cancer tissues is closely correlated with the tumor invasion and metastasis. The mechanism by which Vav3 exerts its invasive and metastatic activity remains unclear. Previous work by del Peso and colleagues indicates that cells transformed by rhoA, rac-1, or vav1 oncogenes have metastatic potential when injected into the blood stream (28) . Invasion-promoting membrane-type matrix metalloproteinases (MT-MMPs) are directly linked to tumorigenesis. Rho family GTPases can also control several molecular events leading to a more motile cellular phenotype, including the expression of MT-MMP (29) (30) (31) . Bartolom e and colleagues showed that the upregulation of MT-MMP expression by CXCL12, a mechanism contributing to melanoma cell invasion, is blocked by knocking down Vav1 and Vav2 expression (32) . The results of this study also indicate that Vav3 knockdown inhibited activities of MMP-2 and MMP-9 in AGS gastric cancer cells. These studies may account in part for the association of overexpression of Vav3 with tumor invasion and metastasis.
It is generally accepted that surgical resection is the most powerful tool for improving the prognosis when early diagnosis of gastric cancer is successful (33) . Unfortunately, most gastric cancers are diagnosed late at a locally advanced stage. Patients with advanced tumors often undergo radical gastrectomy, which leads to a high level of morbidity and does not appreciably diminish the high risk of recurrence (34) . It is essential to precisely predict the risk of recurrence to minimize the adverse effects and maximize the therapeutic effect of treatment of gastric cancer. However, of the available prognostic markers for gastric cancer, the most important is the AJCC stage. However, the prognosis varies among patients with disease at the same stage; hence, it is necessary to have new prognostic markers other than the AJCC stage. Studies related to the prognostic value of Vav proteins are scarce. Fernandez-Zapico and colleagues provided evidence for a strong association between Vav1 overexpression and a poor survival rate in patients with pancreatic cancer (17) . To our knowledge, no studies mention the prognostic significance of Vav3 in human cancers. In the present study, we offered clinical evidence that Vav3 overexpression was inversely correlated with survival and was an independent predictor of poor patient outcome. This is the first study to show that the overexpression of Vav3 can be an independent prognostic marker for gastric cancer. The overexpression of Vav3 is a useful marker for predicting the outcome of patients with gastric cancer who have undergone the surgical resection of a tumor.
Understanding the etiology of gastric cancer is of paramount importance, as it will contribute to our understanding of the molecular pathways that control cancer cell proliferation and provide a theoretical framework for developing novel small molecule inhibitors to combat gastric cancer. This study shows the overexpression of Vav3 in AGS gastric cancer cells. Significantly, depletion of Vav3 by shRNA technology suppresses cell growth, spread, and xenograph proliferation. A recent study shows that astragaloside IV, the major active triterpenoid in Radix Astragali, elicits anticancer activity in HepG2 cells by downregulating the expression of oncogenes such as Vav3.1 (35) . We will examine the anticancer activity of astragaloside IV in gastric cancer cells in the near future.
In summary, this study provides evidence for the clinical significance of overexpressed Vav3 in gastric cancer and indicates that the targeting of Vav3 may be a new therapeutic modality for gastric cancer.
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